Where are ideas coming from?

20180114_115045

News websites (like New York Times, Bloomberg, LA Times) use cookies to track and cap “free browsing” article numbers in a given time period (usually one month).  This can be problematic when I actively search for FDA related news.  So where can you read the FDA related information without paying subscription fees?  Here is a collection of websites I’ve been using to gather Biotech/Pharma information.

  • Biotech/Pharma Company Stock Speculation:
  1. BioPharmCatalyst-profitable tools for biotech investor (free newsletter and paid subscription)
  2. FDA Tracker-Analytics for pharma and biotech traders (paid subscription)
  3. BioRunUp-biotech trading community (free newsletter and paid subscription)
  • Google Alert search for “FDA” news delivering to your email:
  1. Go to Google Alerts.
  2. In the box at the top, enter a topic you want to follow.
  3. To change your settings, click Show options. You can change:
    • How often you get notifications
    • The types of sites you’ll see
    • Your language
    • The part of the world you want info from
    • How many results you want to see
    • What accounts get the alert
  4. Click Create Alert. You’ll get emails whenever we find matching search result
  • Free Newsletters on Biotech/Pharma News:
  1.  Genetic Engineering & Biotechnology News
  2.  FiercePharma
  3.  FierceBiotech
  4.  FierceMedTech
  5.  BioSpace
  6.  SmartBrief
  7.  ClinicalOMICS
  8.  Life Science Leader
  9.  BioPharma Dive
  10.  MedTech Dive
  11.  HealthCare Dive
  12.  Technology Networks
  13.  DDNews– pharma, biotech, life science

It can be overwhelming to see tons of free newsletters coming into email inbox.  Screening headlines is my go to strategy in this information overflow era.  If some articles really attract your attention, then go to the source websites to read more.

Until next time, keep reading and writing.

Advertisements

Take a Thrill Ride of the FDA Advisory Panel’s Decision

Gambling on FDA Advisory Panel Decision?

I recently encountered a short article on how to use FDA’s advisory panel to trade stocks. The article caught my eyes because I am really curious about how Wall Street plays games using FDA.

Pump and Dump Prelude?

My case-in-point is VIVUS, a biopharmaceuticals company whose weight management drug QNEXA (phentermine/topiramate) faced the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee’s vote whether it can go on market on July 15.  On July 13’s Wall Street Journal, a report “FDA Finds ‘Significant’ Weight Loss With Qnexa” and New York Times’s “F.D.A. Review of Diet Pill Relieves Investors” both had positive outlooks for QNEXA to pass panel vote to go on market.  And Leerink Swann analyst Steve Yoo told Reuters, “The topics the FDA raised are in line with what we expected,” and he said “the likelihood of a positive panel vote has increased, which in turn increases the likelihood of approval.”  Three major news sources were upbeat about QNEXA’s clinical trial results.

Science Speaks Louder

To give myself a benefit of doubt, I went to FDA’s website to download over 200 pages document.  I have to admit that I am not experienced enough to make a judgement call, but there are many safety issues that seem to be not negligible.  On July 15, the FDA panel rejected QNEXA due to its questionable safety issues.  Admittedly, share price of VIVUS tanked during after hour trading.

What do I learn from this case?  Timing is everything and beware of analyst’s opinions.  Because some information may not be toxic on the surface, inside it can poison you if you don’t do your own due diligence and give a benefit of doubt on things you don’t really understand.  There are more cases you can practice as many drugs are waiting in line for FDA advisory panels’ examinations.

[Disclosure: I don’t own any of the stocks in the articles I provided the links to, and I don’t endorse any strategies of trading stocks.]

Until next post, keep on reading and writing!!